| Survival | p-value |
---|
| at 12 months (%) | at 24 months (%) | univariate Analysis | multivariate Analysis |
---|
Age |
≤ 65 years | 56 | 19 | | |
> 65 years | 80 | 27 | 0.676 | |
Gender |
Female | 80 | 20 | | |
Male | 65 | 23 | 0.629 | |
Karnofsky performance status |
> 80% | 75 | 30 | | |
≤ 80% | 55 | 10 | 0.041 | 0.077 |
UICC stage |
III | 64 | 21 | | |
IV | 100 | 33 | 0.537 | |
T category |
1–2 | 67 | 0 | | |
3–4 | 68 | 28 | 0.395 | |
N category |
0–1 | 33 | 0 | | |
2–3 | 71 | 25 | 0.299 | |
Histology |
Squamous cell carcinoma | 69 | 25 | | |
Non- Squamous cell carcinoma | 67 | 20 | 0.935 | |
Tobacco consumption (PY) |
0 | 75 | 25 | | |
20–40 | 50 | 12,50 | | |
> 40 | 73 | 27 | 0.758 | |
Grading |
Moderately differentiated | 50 | 50 | | |
Poorly differentiated | 67 | 19 | | |
anaplastic | 100 | 50 | 0.758 | |
PD-L1 expression |
0% | 86 | 29 | | |
≥ 1% | 50 | 19 | 0.048 | 0.648 |
CD8+ TILs density |
≤ 40% | 70 | 40 | | |
> 40% | 61 | 17 | 0.055 | |
TIME type |
I | 100 | 60 | | |
II | 50 | 20 | | |
III | 71 | 14 | | |
IV | 40 | 20 | 0.05 | 0.048 |